On December 20, 2025, Health Canada announced draft Clinical Trial Regulations (CT Regulations) and related guidance that would revamp how clinical trials are regulated in Canada. The draft regulations are intended to clarify and simplify existing rules and
Quebec maintains drug evaluation activities for listing purposes and launches clinical trials
In this post, the Pharma in Brief team reports on two recent developments in the Quebec regulatory landscape related to the COVID-19 crisis.
Adjustments to submission procedure for applications for listing of innovative drugs and blood products on formulary
On
Health Canada consulting on draft guidance distinguishing promotional and non-promotional activities for health products
Health Canada is consulting on a draft guidance document entitled The Distinction Between Promotional and Non-promotional Messages and Activities for Health Products (Draft Guidance), which is intended to replace the current 1996 policy entitled The Distinction Between
Bill 148 : A Bill to limit generic medication procurement by owner pharmacists
Bill 148, An Act to regulate generic medication procurement by owner pharmacists and to amend various legislative provisions, was tabled in the National Assembly on October 5. It will amend An Act respecting Prescription Drug Insurance, introducing the Regulation